Empowered Funds
ANTX icon

Empowered Funds’s AN2 Therapeutics ANTX Stock Holding History

Empowered Funds’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$309K Buy
+58,009
New +$307K ﹤0.01% 2024

Other funds holding ANTX

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Empowered Funds's ANTX Position: Q3 2026 in Review

Empowered Funds opened a new position in AN2 Therapeutics (ANTX) in Q3 2026: 58,009 shares worth $309K. The stake represents ﹤0.01% of the portfolio and ranks #2024 among its holdings.

51 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Empowered Funds held 58,009 shares of AN2 Therapeutics worth $309K as of Q3 2026.
  • AN2 Therapeutics was a new Empowered Funds position in Q3 2026.
  • AN2 Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2024 holding.
  • 51 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.